期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 12, 期 -, 页码 2279-2290出版社
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/2230
关键词
transcription; Wilms tumor; WT1; vascular endothelial growth factor; VEGF; prostate cancer; androgen; transfection; electrophoretic mobility shift; assay; EMSA
资金
- NATIONAL CANCER INSTITUTE [R15CA113360] Funding Source: NIH RePORTER
- NCI NIH HHS [R15 CA113360, R15 CA113360-01, R15CA113360] Funding Source: Medline
Understanding angiogenesis and growth control is central for elucidating prostate tumorigenesis. However, the mechanisms of activation of the angiogenic gene, vascular endothelial growth factor (VEGF) are complex and its regulation in prostate cancer is not well understood. In previous studies, VEGF expression levels were correlated with altered levels of the zinc finger transcription factor, WT1. Since the VEGF promoter has several potential WT1 binding sites and WT1 regulates many growth control genes, here we assessed whether WT1 might also regulate VEGF transcription. Using transfection and DNA binding assays, functional WT1 binding sites were localized within the proximal VEGF promoter. Transfection of the DDS-WT1 (R394W) zinc finger mutant had no significant effect on VEGF-luciferase reporter activity, suggesting that an intact zinc finger DNA binding domain was required. Interestingly, WT1-mediated regulation of VEGF reporter constructs varied in different cell types. In androgen-responsive, LNCaP prostate cancer cells, hormone treatment enhanced WT1-mediated activation of the VEGF promoter constructs. Overall, these results suggest that WT1 transcriptionally regulates VEGF through interaction of its zinc finger DNA binding domain with the proximal GC-rich VEGF promoter. These findings may shed light on the role of WT1 in angiogenesis and prostate cancer progression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据